Tag Archives: cytarabine

Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Eli Lilly (NYSE: LLY) said that […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More

Much of the East Coast is green today for St. Patrick’s Day, but overall it’s been another red week for biotech. Indexes continued to slump despite some good data from the likes of Celator Pharmaceuticals of Ewing, NJ. More on that and the rest of your East Coast news below. —The battle between rival developers […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More

At ASH, Sunesis Dices Data to Argue For “Failed” Leukemia Drug

No drug has been approved to treat acute myeloid leukemia in four decades. As two specialists in the field wrote a couple years ago, “We indeed regularly administer the same chemotherapy regimens that became standard care for AML in the 1970s, back when each of us was playing Little League baseball.” South San Francisco, CA-based […]

Posted in Boston blog main, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories, Texas blog main | Tagged , , , , , , , , , , , , , , , , | Comments Off on At ASH, Sunesis Dices Data to Argue For “Failed” Leukemia Drug